<DOC>
	<DOCNO>NCT02090322</DOCNO>
	<brief_summary>The Retinopathy Prematurity ( ROP ) Retina 's pathology premature baby , 's characterize proliferation vascular tissue grow limit vascular retina avascular retina . The altered regulation Vascular Endothelial Grow Factor ( VEGF ) propose one principal factor pathogenesis ROP . The ROP classify : location ( zone I , II , III ) , extension ( hour 1 12 ) stage ( 1,2,3,4a,4b,5 ) feature vessel ( normal , pre-plus plus ) . With diagnosis ROP type 1 ( ROP zone I stage plus , zone I stage 3 without plus , zone II stage 2 3 plus ) treatment begin ROP type 2 maintain observation . The altered regulation Vascular Endothelial Grow Factor ( VEGF ) propose one principal factor pathogenesis ROP .</brief_summary>
	<brief_title>Bevacizumab 0.500MG Intravitreal There Is n't Lower Than 0.625MG Treatment ROP Type 1</brief_title>
	<detailed_description>ustification : Before treatment Cryotherapy standard gold laser , however retina tissue destroy , loss visual field procedure need general anesthesia , may trans post surgical complication . Currently intravitreal antiangiogenics employ ( inhibit VEGF ) , specially Bevacizumab , 's quickly procedure topic anesthesia low price , good result . It 's know intravitreal bevacizumab arrives blood n't report secondary efects moment , however , want demonstrate weight volume premature baby 's eye , need low dosis less sistemic effect . HYPOTHESIS : The injection 0.500 mg Bevacizumab intravitreal isnt low 0.625 mg Bevacizumab intravitreal regression ROP type 1 OBJECTIVE : Demonstrate 0.500mg Bevacizumab intravitreal n't inferior 0.625mg resolution ROP type 1 . METHODOLOGY : No inferiority study . ECCA . We go include premature patient prematures less 32SDG and/or 1500g less 36SDG factor risk . They go examine week fourth , de diagnosis ROP type 1 , go inject intravitreal Bevacizumab , dosis randomize ( 0.500mg 0.625mg ) go examine another time first week , two week , first month , second sixth month treatment , warrant la resolution ROP . The size simple 30 patient group ( Dosis A Dosis B ) . We go describe date infection , age baby bevacizumab inyected . When ROP regression , go describe date , finally go describe age go baby ROP regression . It go important determine concept exit failure . And finally demonstrate two dosage good result</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Prematurity , low weight , oxygen , retinopathy prematurity type 1 Retinopathy prematurity type 2 , retinopathy prematurity stage 4 5</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>ROP</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>No inferiority</keyword>
</DOC>